Can a new antibiotic tame tough urinary infections? a safety trial begins
NCT ID NCT07719257
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental antibiotic called TUL108 in healthy volunteers to see if it is safe and how the body processes it. The drug is being developed for complicated urinary tract infections (cUTI), which can be difficult to treat with standard antibiotics. Researchers will give single and multiple doses by IV infusion and monitor for side effects. The study does not yet test whether TUL108 actually cures infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental antibiotic called TUL108
- What this could lead to
- If safe, TUL108 could become a new treatment option for complicated urinary tract infections, which are often hard to treat due to antibiotic resistance.
- What could go wrong
- This is an early phase 1 trial in healthy people, not patients. It only tests safety and how the drug moves through the body, not whether it actually works against infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPLICATED URINARY TRACT INFECTIONS(CUTI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital affiliated to Fudan University
Shanghai, China